Quoin Pharmaceuticals Expands Netherton Syndrome Clinical Trials Internationally

Quoin Pharmaceuticals Ltd. has announced the further expansion of its ongoing clinical studies for Netherton Syndrome (NS) to include two new international sites in the United Kingdom. These sites are Great Ormond Street Hospital and St. Thomas’ Hospital, both located in London. These hospitals are recognized centers of excellence for the treatment of Netherton Syndrome patients in the UK and have available cohorts of patients who may be eligible to participate in Quoin's studies.

A Principal Investigator (PI) has been appointed for the UK studies, and a Clinical Research Organization has been engaged. These new clinical sites in the UK will operate under Quoin’s open Investigational New Drug (IND) application with the US Food and Drug Administration. In addition to the sites in the UK, Quoin has also been preparing for the opening of additional sites in several other Western European countries and is concluding a feasibility study in multiple Eastern European countries, all of which have available cohorts of NS patients.

Dr. Michael Myers, CEO of Quoin, expressed his satisfaction with this development, stating that the expansion into two highly esteemed clinical centers in the UK, along with plans for additional sites in Western and Eastern Europe, highlights the company's commitment to rapidly enrolling participants in their studies. This effort aims to potentially deliver the first approved treatment for this underserved patient population.

Quoin Pharmaceuticals is currently conducting two clinical trials evaluating QRX003, a topical lotion, for the treatment of Netherton Syndrome, a rare and inherited genetic disease. The company's innovative pipeline includes five products in development that have the potential to target a wide range of rare and orphan diseases, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and Epidermolysis Bullosa.

Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing therapeutic products for rare and orphan diseases. Their mission is to address unmet medical needs for patients, their families, communities, and care teams. The company is committed to delivering innovative treatments to improve the quality of life for those affected by these rare conditions.

In summary, Quoin Pharmaceuticals Ltd. is expanding its clinical studies for Netherton Syndrome by opening two new sites in the UK and preparing for additional sites in other parts of Europe. With a dedicated team and a robust pipeline, Quoin aims to provide effective treatments for rare and orphan diseases, bringing hope and potential solutions to those in need.